問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Taipei City Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • pidb_editor
  • 103Taipei CityDa Tong

Recruiting Trial

2Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

28Cases

2015-12-01 - 2017-12-31

Phase III

An Open-Label Multicenter Study Assessing the Long-Term Safety of a Once-Weekly and Once-Monthly, Long-Acting Subcutaneous Injection Depot of Buprenorphine (CAM2038) in Adult Outpatients with Opioid Use Disorder.

  • Condition/Disease

    opioid use disorder

  • Test Drug

    CAM2038 q1w（buprenorphine FluidCrystal®每週一次長效注射劑）; CAM2038 q4w（buprenorphine FluidCrystal®每月一次長效注射劑）

Participate Sites
3Sites

Terminated3Sites

2010-09-01 - 2012-12-31

Phase III

A multicenter, randomized, double-blind, fixed-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo in subjects with an acute exacerbation of schizophrenia (Phase 3 ; Protocol No. P06124)

  • Condition/Disease

    Schizophrenia

  • Test Drug

    Asenapine (SCH 900274)

Participate Sites
13Sites

Terminated13Sites

黃宗正
National Taiwan University Hospital

Division of Psychiatry

2010-10-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2013-12-01 - 2016-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2014-06-01 - 2018-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2010-12-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2010-12-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2012-01-05 - 2013-06-30

Phase III

A phase 3, multicenter, randomized, double-blind, placebo-controlled Trial of Fixed-dose OPC-34712 (4,2, and 1 mg/day) in the Treatment of Adults With Acute Schizophrenia

  • Condition/Disease

    Schizophrenia

  • Test Drug

    OPC-34712

Participate Sites
4Sites

Terminated4Sites

藍先元
China Medical University Hospital

Division of Psychiatry

2012-03-30 - 2014-06-30

Phase III

A phase 3, Multicenter, Open-label trial to evaluate the Safety and Tolerability of Oral OPC-34712 as Maintenance Treatment in Adults with Schizophrenia

  • Condition/Disease

    Schizophrenia

  • Test Drug

    OPC-34712

Participate Sites
4Sites

Terminated4Sites

藍先元
China Medical University Hospital

Division of Psychiatry

2010-01-01 - 2010-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB